News FDA panel narrowly backs heart benefit of BI/Lilly diabetes ... FDA advisers voted 12-11 that Jardiance also reduces cardiovascular risks.
News Victoza disappoints on cardio benefits, lifts rival Jardianc... Victoza results are significant, but fell short of investors' expectations.
News Pharma looking to dual-action diabetes drugs to boost sales Pharma using FDA-mandated trials to give a commercial advantage.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
